Wall Street brokerages expect Steris PLC (NYSE:STE) to announce $1.26 earnings per share for the current quarter, according to Zacks. Three analysts have provided estimates for Steris’ earnings, with the lowest EPS estimate coming in at $1.23 and the highest estimate coming in at $1.30. Steris posted earnings of $1.10 per share during the same quarter last year, which suggests a positive year over year growth rate of 14.5%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 5th.

On average, analysts expect that Steris will report full year earnings of $5.43 per share for the current year, with EPS estimates ranging from $5.35 to $5.47. For the next financial year, analysts expect that the firm will report earnings of $5.97 per share, with EPS estimates ranging from $5.90 to $6.03. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Steris.

Steris (NYSE:STE) last issued its quarterly earnings results on Monday, August 5th. The medical equipment provider reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.12. The company had revenue of $696.80 million for the quarter, compared to analyst estimates of $674.12 million. Steris had a net margin of 11.22% and a return on equity of 13.80%. Steris’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.00 earnings per share.

STE has been the subject of a number of analyst reports. Stephens lifted their target price on shares of Steris from $135.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 15th. Zacks Investment Research raised shares of Steris from a “hold” rating to a “buy” rating and set a $146.00 target price for the company in a research note on Tuesday, April 30th. KeyCorp lifted their target price on shares of Steris from $135.00 to $138.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 15th. Finally, JMP Securities lifted their target price on shares of Steris from $135.00 to $150.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 22nd. Five equities research analysts have rated the stock with a buy rating, Steris currently has a consensus rating of “Buy” and a consensus target price of $148.20.

NYSE STE traded up $0.77 during mid-day trading on Friday, reaching $152.74. 344,700 shares of the stock were exchanged, compared to its average volume of 412,698. Steris has a one year low of $99.14 and a one year high of $156.12. The stock has a 50 day simple moving average of $150.09 and a 200-day simple moving average of $133.86. The stock has a market cap of $12.85 billion, a P/E ratio of 31.24 and a beta of 0.98. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.41 and a quick ratio of 1.87.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 26th. Shareholders of record on Tuesday, September 10th will be paid a $0.37 dividend. This is an increase from Steris’s previous quarterly dividend of $0.34. This represents a $1.48 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Monday, September 9th. Steris’s payout ratio is 27.81%.

In other Steris news, CEO Walter M. Rosebrough, Jr. sold 102,500 shares of Steris stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $151.78, for a total value of $15,557,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 119,000 shares of Steris stock in a transaction on Friday, May 31st. The shares were sold at an average price of $132.56, for a total transaction of $15,774,640.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 357,351 shares of company stock valued at $50,364,268. Insiders own 2.36% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. William Blair Investment Management LLC acquired a new position in shares of Steris during the first quarter valued at about $102,859,000. Invesco Ltd. grew its holdings in shares of Steris by 103.3% during the second quarter. Invesco Ltd. now owns 1,141,634 shares of the medical equipment provider’s stock valued at $169,967,000 after buying an additional 579,965 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Steris by 6.1% during the second quarter. BlackRock Inc. now owns 9,052,709 shares of the medical equipment provider’s stock valued at $1,347,769,000 after buying an additional 522,254 shares during the last quarter. AJO LP grew its holdings in shares of Steris by 4,952.8% during the first quarter. AJO LP now owns 504,922 shares of the medical equipment provider’s stock valued at $64,645,000 after buying an additional 494,929 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Steris by 165.1% during the second quarter. JPMorgan Chase & Co. now owns 792,562 shares of the medical equipment provider’s stock valued at $116,142,000 after buying an additional 493,578 shares during the last quarter. 85.45% of the stock is owned by hedge funds and other institutional investors.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

Further Reading: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.